<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01494402</url>
  </required_header>
  <id_info>
    <org_study_id>D961SC00001</org_study_id>
    <nct_id>NCT01494402</nct_id>
  </id_info>
  <brief_title>Study to Assess the Bioequivalence Between D961S and Esomeprazole/Buffered Acetylsalicylic Acid (ASA) in Japanese Healthy Male Subjects</brief_title>
  <official_title>A Phase I, Open Label, Randomized, Single Center, 2 Way Crossover Bioequivalence Study Comparing D961S (a Fixed-dose Combination Capsule of Esomeprazole 20 mg and Acetylsalicylic Acid 81 mg) With a Free Combination of Esomeprazole Capsule 20 mg + Buffered Acetylsalicylic Acid Tablet 81 mg After Repeated Oral Administration in Japanese Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess bioequivalence between D961S and esomeprazole/buffered
      ASA, safety, tolerability of esomeprazole in combination with ASA and pharmacokinetics (PK)
      of D961S, esomeprazole and buffered ASA following repeated administration in healthy male
      Japanese subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, Open label, Randomized, Single center, 2 way Crossover Bioequivalence Study
      Comparing D961S (a Fixed-dose Combination Capsule of Esomeprazole 20 mg and Acetylsalicylic
      Acid 81 mg) with a Free Combination of Esomeprazole Capsule 20 mg + Buffered Acetylsalicylic
      Acid Tablet 81 mg After Repeated Oral Administration in Japanese Healthy Male Subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Description of bioequivalence of D961S to combination of esomeprazole + buffered ASA in terms of Area under the plasma concentration(AUCτ).</measure>
    <time_frame>Baseline, which is 30 minutes before dose at day 5 of treatment period, till day 6</time_frame>
    <description>All PK variables at each time point will be listed by subject and summarised for each treatment using appropriate descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of bioequivalence of D961S to combination of esomeprazole + buffered ASA in term maximum plasma concentration (Cmax,ss)</measure>
    <time_frame>Baseline, which is 30 minutes before dose at day 5 of treatment period, till day 6</time_frame>
    <description>All PK variables at each time point will be listed by subject and summarised for each treatment using appropriate descriptive statistics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of D961S PK profile comparing to esomeprazole and ASA combination in terms of AUC0-t,ss, mean residence time (MRT), time to reach Cmax (tmax,ss) and t1/2,ss of esomeprazole and ASA, and AUCτ, Cmax,ss, AUC0-t,ss, MRT, tmax,ss and t1/2,ss of SA</measure>
    <time_frame>Baseline, which is 30 minutes before dose at day 5 of treatment period, till day 6</time_frame>
    <description>All PK variables and plasma concentrations of esomeprazole, ASA and SA at each time point will be listed by subject and summarised for each treatment using appropriate descriptive statistics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of Safety and tolerability profile of esomeprazole in combination with ASA in terms of adverse events, clinical laboratory tests, blood pressure, pulse rate and body temperature.</measure>
    <time_frame>Pre-entry, Day 5 of treatment period and follow up (5-7 days after last dose)</time_frame>
    <description>Descriptive statistics will be provided for all safety variables, and the analyses will be performed according to the actual treatment. No formal comparison will be performed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Bioequivalence Study</condition>
  <arm_group>
    <arm_group_label>D961S</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 way crossover</description>
  </arm_group>
  <arm_group>
    <arm_group_label>esomeprazole + buffered acetylsalicylic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 way crossover</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D961S</intervention_name>
    <description>Oral gelatine capsule</description>
    <arm_group_label>D961S</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Oral HPMC capsule</description>
    <arm_group_label>esomeprazole + buffered acetylsalicylic acid</arm_group_label>
    <other_name>Nexium® capsule 20 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buffered acetylsalicylic acid</intervention_name>
    <description>Tablet</description>
    <arm_group_label>esomeprazole + buffered acetylsalicylic acid</arm_group_label>
    <other_name>Bufferin Combination Tablet A81</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Japanese males 20-45 years of age

          -  Classified as homo-EM

          -  Negative for HIV, Hepatitis B, Hepatitis C and syphilis

          -  Body Mass Index (BMI=weight/height2) 19-27 (kg/m2)

          -  Body weight 50-85 kg

        Exclusion Criteria:

          -  Significant clinical illness from 2 weeks preceding the pre-entry visit to the
             randomization

          -  Past or present cardiac, renal, hepatic, neurological or gastrointestinal disease

          -  Need for concomitant medication in the study

          -  Past or present NSAIDs induced asthma

          -  History of bleeding diathesis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Study site</name>
      <address>
        <city>Hakata</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2011</study_first_submitted>
  <study_first_submitted_qc>December 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 19, 2011</study_first_posted>
  <last_update_submitted>April 6, 2012</last_update_submitted>
  <last_update_submitted_qc>April 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy volunteer, Japanese males, homo-EM</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

